JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Penumbra Inc

Closed

SectorHealthcare

233.1 -0.67

Overview

Share price change

24h

Current

Min

229.61

Max

238.3

Key metrics

By Trading Economics

Income

6M

45M

Sales

15M

339M

P/E

Sector Avg

65.78

37.461

Profit margin

13.336

Employees

4,500

EBITDA

1.9M

51M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+29.48% upside

Dividends

By Dow Jones

Next Earnings

5 lis 2025

Market Stats

By TradingEconomics

Market Cap

758M

9.7B

Previous open

233.77

Previous close

233.1

News Sentiment

By Acuity

100%

0%

359 / 373 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Penumbra Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 paź 2025, 23:50 UTC

Hot Stocks

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 paź 2025, 23:25 UTC

Earnings

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 paź 2025, 23:18 UTC

Earnings

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 paź 2025, 22:20 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 paź 2025, 22:13 UTC

Earnings

Wal-Mart de Mexico Net Profit Falls in 3Q

28 paź 2025, 21:38 UTC

Earnings

Correction to Visa Sales Jump Article

28 paź 2025, 21:17 UTC

Earnings

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 paź 2025, 21:07 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- Update

28 paź 2025, 21:02 UTC

Earnings

Mondelez Tempers Outlook as Costs Rise

28 paź 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 paź 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 paź 2025, 23:02 UTC

Earnings

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 paź 2025, 23:01 UTC

Earnings

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 paź 2025, 22:46 UTC

Earnings

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 paź 2025, 22:45 UTC

Earnings

SK Hynix 3Q Net KRW12.6T >000660.SE

28 paź 2025, 22:44 UTC

Earnings

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 paź 2025, 22:43 UTC

Earnings

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 paź 2025, 22:42 UTC

Earnings

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 paź 2025, 22:40 UTC

Earnings

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 paź 2025, 22:40 UTC

Earnings

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 paź 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 paź 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 paź 2025, 22:22 UTC

Earnings

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 paź 2025, 22:20 UTC

Earnings

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 paź 2025, 22:02 UTC

Earnings

Review & Preview: Earnings Extravaganza -- Barrons.com

28 paź 2025, 21:42 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

28 paź 2025, 21:42 UTC

Market Talk
Earnings

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 paź 2025, 21:20 UTC

Earnings

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 paź 2025, 21:19 UTC

Earnings

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 paź 2025, 21:18 UTC

Earnings

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer Comparison

Price change

Penumbra Inc Forecast

Price Target

By TipRanks

29.48% upside

12 Months Forecast

Average 304.92 USD  29.48%

High 350 USD

Low 265 USD

Based on 16 Wall Street analysts offering 12 month price targets forPenumbra Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

13

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

288.28 / 292.9394Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

359 / 373 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat